<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621621</url>
  </required_header>
  <id_info>
    <org_study_id>PS-010</org_study_id>
    <nct_id>NCT00621621</nct_id>
  </id_info>
  <brief_title>CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)</brief_title>
  <acronym>PS-010</acronym>
  <official_title>CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Atrial Fibrillation Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Atrial Fibrillation Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post approval study of heart block is to gather additional information
      regarding how often patients develop heart block (atrioventricular block) after having
      standard ablation procedure using cryotherapy with the Freezor™ catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the lack of enrollments for the trial. The FDA and Medtronic discussed the inclusion
      of data found from from published literature (external studies) to corroborate study
      endpoint. The FDA allowed this data and the study was closed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device or Procedure Related AV Block Persistent Through Discharge From Hospital.</measure>
    <time_frame>After 250 subjects have been enrolled.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AV Block That Requires the Insertion of a Permanent Pacemaker: Defined as the Insertion of a Permanent Pacemaker, as Assessed During Defined Study Follow up.</measure>
    <time_frame>After 250 subjects have been enrolled.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Tachycardia, Atrioventricular Nodal Reentry</condition>
  <arm_group>
    <arm_group_label>Freezor Catheter for AVNRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External Data Supporting the Study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Freezor® Cardiac Cryoablation Catheter CryoConsole System</intervention_name>
    <description>cryoablation</description>
    <arm_group_label>Freezor Catheter for AVNRT</arm_group_label>
    <arm_group_label>External Data Supporting the Study</arm_group_label>
    <other_name>7F Freezor Cardiac CryoAblation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Some inclusion criteria can only be established during the electrophysiologic study (EPS);
        thus there are two groups of inclusion criteria.

        For inclusion in the study subjects must fulfill ALL of the following criteria:

        Pre-EPS inclusion criteria:

          1. Patients with a clinical history of AVNRT who are referred for ablation.

          2. Patients willing to provide written informed consent.

        Post-EPS inclusion criteria:

        1. Patients with EPS-documented AVNRT

        Exclusion Criteria:

        ANY of the following is regarded as a criterion for excluding a subject from the study:

          1. Patients with any pre-existing AV block.

          2. Patients with known cryoglobulinemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lehmann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehmann Consulting</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>63198-7835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center and the New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Friedman PL, Dubuc M, Green MS, Jackman WM, Keane DT, Marinchak RA, Nazari J, Packer DL, Skanes A, Steinberg JS, Stevenson WG, Tchou PJ, Wilber DJ, Worley SJ. Catheter cryoablation of supraventricular tachycardia: results of the multicenter prospective &quot;frosty&quot; trial. Heart Rhythm. 2004 Jul;1(2):129-38.</citation>
    <PMID>15851143</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>April 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2015</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrioventricular nodal reentrant tachycardia</keyword>
  <keyword>AVNRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Atrioventricular Nodal Reentry</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Focal Cryoablation Group</title>
          <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
Freezor® Cardiac Cryoablation Catheter CryoConsole System: cryoablation</description>
        </group>
        <group group_id="P2">
          <title>External Data Supporting the Study</title>
          <description>Data from published reports that include subjects that met inclusion criteria for study and contained data of Heart block.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105">Date of Post- Approval Study protocol approval</participants>
                <participants group_id="P2" count="705"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75">Treated with the experimental catheter</participants>
                <participants group_id="P2" count="705"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects were exited at EP study</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 105 subjects gave actual consent in the study. Of the 105 consented 75 went on to have an ablation procedure performed. Data from 675 subjects were taken from published data that met inclusion criteria with publication search approved by the FDA.</population>
      <group_list>
        <group group_id="B1">
          <title>Focal Cryoablation Group</title>
          <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
Freezor® Cardiac Cryoablation Catheter CryoConsole System: cryoablation</description>
        </group>
        <group group_id="B2">
          <title>Subjects Consented in the Study Not Ablated</title>
          <description>Actual Subjects that were consented in the study that did not meet inclusion criteria.</description>
        </group>
        <group group_id="B3">
          <title>Subjects Collected From Published Data</title>
          <description>Published evidence about the safety and efficacy of using Medtronic’s Freezor® 4 mm CryoCatheter has been reported since the initiation of the CryoFACTS-PAS. The results reported in the literature provide the supplemental data in the same study population as in the PAS and are included to meet the study objectives, as agreed upon with the FDA.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="675"/>
            <count group_id="B4" value="780"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="17.8"/>
                    <measurement group_id="B2" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B3" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B4" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline demographics were only collected for actual enrolled subjects (n=75) That were ablated. This data was not available for subjects enrolled from publicaton data (675).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B3" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B3" value="NA">Data was not collected on subjects that were not ablated by the site.</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="NA">Regions were not collected from Publication data</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device or Procedure Related AV Block Persistent Through Discharge From Hospital.</title>
        <time_frame>After 250 subjects have been enrolled.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Focal Cryoablation Group</title>
            <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
Freezor® Cardiac Cryoablation Catheter CryoConsole System: cryoablation</description>
          </group>
          <group group_id="O2">
            <title>External Data Supporting the Study</title>
          </group>
        </group_list>
        <measure>
          <title>Device or Procedure Related AV Block Persistent Through Discharge From Hospital.</title>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AV Block That Requires the Insertion of a Permanent Pacemaker: Defined as the Insertion of a Permanent Pacemaker, as Assessed During Defined Study Follow up.</title>
        <time_frame>After 250 subjects have been enrolled.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Freezor Catheter for AVNRT</title>
            <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmiacryoablation</description>
          </group>
          <group group_id="O2">
            <title>External Data Supporting the Study</title>
            <description>This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.</description>
          </group>
        </group_list>
        <measure>
          <title>AV Block That Requires the Insertion of a Permanent Pacemaker: Defined as the Insertion of a Permanent Pacemaker, as Assessed During Defined Study Follow up.</title>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Focal Cryoablation Group</title>
          <description>Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
Freezor® Cardiac Cryoablation Catheter CryoConsole System: cryoablation</description>
        </group>
        <group group_id="E2">
          <title>External Data Supporting the Study</title>
          <description>Subjects from publication search with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
Freezor® Cardiac Cryoablation Catheter CryoConsole System: cryoablation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slow enrollment in the trial showed limited the amount of available data. Detailed subject data from the published literature was not available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adam Cline, MD, MSc.- Sr. Clinical Research Specialist</name_or_title>
      <organization>Medtronic- AF Solutions</organization>
      <phone>763-526-9601</phone>
      <email>adam.cline@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

